Session » Systemic Sclerosis & Related Disorders – Clinical Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1574

Therapeutic Strategy in Patients with Mixed Connective Tissue Disease: A Multicenter Retrospective Study in the French MCTD Cohort

10:30AM-12:30PM: Abstract Number: 1575

Anti-U1RNP Antibodies Are Associated with a Distinct Clinical Phenotype and a Worse Survival in Patients with Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1561

Association of Large Vessel Vasculitis and Development of SSc and SSc-Associated Antibodies: Impact of Pulmonary Arterial Hypertension

10:30AM-12:30PM: Abstract Number: 1578

Association of Systemic Sclerosis and Other Systemic Autoimmune Disease Diagnosis with Increasing Anti-RNA Polymerase III Antibodies

10:30AM-12:30PM: Abstract Number: 1572

Associations Between the Gut Microbiota, Ultra-Processed Food Intake, and Gastrointestinal Tract Symptoms in Patients with Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1562

Autoantibody Associations with Disease Manifestations in Patients with Early Diffuse Cutaneous Systemic Sclerosis: The Prospective Registry of Early Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1560

Changes of Cerebral Structure and Perfusion Vary in Different Subtypes of Systemic Sclerosis: A Brain Magnetic Resonance Imaging Study

10:30AM-12:30PM: Abstract Number: 1585

Characterization of the Fecal Metabolome in Early Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1566

Comparative Analysis of Clinical Features and Outcomes in Late Onset vs. Early Onset Scleroderma Renal Crisis – A Multicenter Study

10:30AM-12:30PM: Abstract Number: 1570

Deconvolution of the Lipidomic Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: Lipid Biomarker Features That Predict Disease Progression in Skin and Lung

10:30AM-12:30PM: Abstract Number: 1568

Distribution of Proteinuria in Scleroderma Renal Crisis: A Multi-Center Study

10:30AM-12:30PM: Abstract Number: 1591

Domains and Outcome Measures for the Assessment of Digital Vasculopathy and Raynaud Phenomenon in Juvenile Systemic Sclerosis: A Systematic Review

10:30AM-12:30PM: Abstract Number: 1573

Early Scleroderma with Non-Raynaud’s Symptoms Prior to Raynaud’s Onset Is Associated with Rapid Progression to Diffuse Skin Disease and Joint Contractures

10:30AM-12:30PM: Abstract Number: 1584

Efficacy of Tofacitinib in the Treatment of Early Diffuse Cutaneous Systemic Sclerosis: A Clinical Study in Bangladesh

10:30AM-12:30PM: Abstract Number: 1577

Elevated Neutrophil Extracellular Traps in Systemic Sclerosis-associated Vasculopathy and Suppression by a Synthetic Prostacyclin Analog

10:30AM-12:30PM: Abstract Number: 1557

Estimation of Cardiovascular Risk in Patients with Systemic Sclerosis – Accuracy of Tools Based on SCORE and Its Modifications Compared to Ultrasound Examination of Subclinical Atherosclerosis

10:30AM-12:30PM: Abstract Number: 1579

Exploring the Cardiovascular Complications of Pulmonary Arterial Hypertension in Individuals with Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1571

Growth Differentiation Factor 15 Is a Serum Biomarker and Pathogenic Factor of Progressive Fibrosis in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1582

Impact of Immunosuppressive Treatment on Development and Survival in Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)

10:30AM-12:30PM: Abstract Number: 1564

Incidence of Posttraumatic Stress Disorder Secondary to the Diagnosis of Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1558

Mapping in Healthy Subjects Different Body Areas for Dermal Thickness and Skin Hardness by High Frequency Sonography and Durometry

10:30AM-12:30PM: Abstract Number: 1590

Milder ILD with Preserved Lung Function Significantly Contributes to Respiratory Caused Mortality in SSc

10:30AM-12:30PM: Abstract Number: 1581

Neutrophil-to- lymphocyte Ratio: A Possible Biomarker for Clinical Response After Autologous Hematopoietic Stem Cell Transplantation

10:30AM-12:30PM: Abstract Number: 1576

New Patient-Reported Outcome Measures for Early Systemic Sclerosis Using the FDA Guidance on Patient Reported Outcome Measures

10:30AM-12:30PM: Abstract Number: 1580

Overt Polyautoimmunity and Its Risk Factors in a Multicenter Cohort of Systemic Sclerosis Patients

10:30AM-12:30PM: Abstract Number: 1587

Predictors of Body Mass Index in an Early Systemic Sclerosis Cohort

10:30AM-12:30PM: Abstract Number: 1565

Prevalence and Risk Factors of Lower Extremities Arterial Disease in Systemic Sclerosis: Preliminary Data from a Single Centre Multidisciplinary Study

10:30AM-12:30PM: Abstract Number: 1563

Prevalence, Risk Factors and Associations for Osteoporosis in Postmenopausal Women with Scleroderma

10:30AM-12:30PM: Abstract Number: 1569

Scleroderma Renal Crisis – Different Phenotypes and Patient Trajectories

10:30AM-12:30PM: Abstract Number: 1567

Systemic Sclerosis Is Associated with Sub-Clinical Abnormalities in Myocardial Energetics, Perfusion and Increased Fibrosis

10:30AM-12:30PM: Abstract Number: 1583

The Association of Weakpositive Anti-RNA Polymerase III Antibodies with the Diagnosis and Complications of Systemic Sclerosis and Other Systemic Autoimmune Diseases

10:30AM-12:30PM: Abstract Number: 1586

The Relationship Between the Presence, Quantity and Distribution of Cutaneous Telangiectasia and Other Vascular Manifestations of Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1588

Validation of a Lung Ultrasound Interpretation Criteria for Interstitial Lung Disease Screening in Systemic Sclerosis and Inflammatory Myopathy

10:30AM-12:30PM: Abstract Number: 1559

Vectorcardiography for Identification of Systemic Sclerosis Patients at Risk for Pulmonary Hypertension

10:30AM-12:30PM: Abstract Number: 1589

Whole Skin Gene Expression Analysis Identifies Discrete Modules That Differentiate Antinuclear Antibody Subsets in Systemic Sclerosis

« View all sessions from this meeting